|Articles|July 8, 2014

Special Reports

  • Hematologic Malignancies
  • Volume 1
  • Issue 1

IPI-145 and ABT-199 for Lymphoid Malignancies

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses IPI-145 and ABT-199 for the treatment of lymphoid malignancies.

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses IPI-145 and ABT-199 for the treatment of lymphoid malignancies.

Learn more about inhibiting BCL-2 > >


Latest CME